Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Vizient to Present at FDA CDER Quality Management Maturity Workshop

May 25, 2022 at 06:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Vizient Group Senior Vice President, Pharmacy Solutions Dan Kistner will present at the Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Quality Management Maturity (QMM) Workshop, which is being held May 24-25, 2022. The two-day workshop will highlight the FDA’s work to develop a QMM rating program that will objectively assess and rate the QMM of facilities manufacturing drug products and active pharmaceutical ingredients.

On the second day of the workshop titled, “Development and Impact of Quality Ratings Systems,” Kistner will share Vizient’s efforts to support a more resilient supply chain and how group purchasing organizations could utilize QMM ratings.

“A QMM rating system will promote greater transparency of the maturity of quality management practices of drug manufacturers, which will help to address supply chain issues and mitigate drug shortages so that patients have access to critical drugs when they need them,” said Dan Kistner, group senior vice president, pharmacy solutions. “We commend the FDA for its commitment to ensuring that high-quality drugs are available for patients and for providing this forum to foster collaboration to end drug shortages. We need all stakeholders working together to increase supply chain resiliency.”

Kistner will join key FDA and pharmacy leaders on a Q&A panel to conclude the session.

Concurrent to the QMM Workshop, the FDA is soliciting input from stakeholders until June 7, 2022 that will help to inform the future regulatory approach for a Quality Metrics Reporting Program to which Vizient plans to share comments.

About Vizient, Inc.

Vizient, Inc., the nation’s largest health care performance improvement company, serves more than 50% of the nation’s acute care providers, which includes 97% of the nation’s academic medical centers, and more than 20% of ambulatory care providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume. Vizient’s solutions and services improve the delivery of high-value care by aligning cost, quality and market performance. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.